Inactive Instrument
Guided Therapeutics Inc Share Price OTC Bulletin Board
Stocks
US40171F2048
Advanced Medical Equipment & Technology
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 16/06 | Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA | CI |
| 15/05 | Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Market Cap | 2.9Cr 2.53Cr 2.34Cr 2.16Cr 4.09Cr 276.21Cr 4.16Cr 28Cr 11Cr 136.07Cr 11Cr 11Cr 467.79Cr | P/E 2024 |
-3x | P/E 2025 | -12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3.18Cr 2.78Cr 2.57Cr 2.37Cr 4.5Cr 303.64Cr 4.58Cr 31Cr 12Cr 149.58Cr 12Cr 12Cr 514.24Cr | EV / Sales 2024 |
1,649x | EV / Sales 2025 | 64.4x |
| Free-Float |
63.48% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Faupel
CEO | Chief Executive Officer | 70 | 06/03/2023 |
| Chief Tech/Sci/R&D Officer | 70 | 02/12/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
John Imhoff
BRD | Director/Board Member | 76 | 10/04/2006 |
Richard Blumberg
BRD | Director/Board Member | 69 | 10/11/2016 |
Mark Faupel
BRD | Director/Board Member | 70 | 01/12/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.45% | +0.69% | +21.20% | +0.21% | 20TCr | ||
| -1.16% | -4.51% | -20.56% | +17.03% | 14TCr | ||
| +1.57% | +0.57% | -2.83% | -16.40% | 14TCr | ||
| -0.49% | -0.82% | -56.62% | -14.66% | 6.65TCr | ||
| +0.96% | -2.29% | +18.14% | -0.96% | 5.31TCr | ||
| +1.37% | -0.26% | -24.35% | -32.05% | 4.41TCr | ||
| +0.52% | +2.75% | +8.93% | +11.91% | 3.79TCr | ||
| -0.19% | -0.75% | +6.66% | +39.97% | 3.7TCr | ||
| 0.00% | -1.32% | -13.88% | -20.80% | 2.94TCr | ||
| Average | +0.34% | -0.75% | -7.03% | -1.75% | 8.32TCr | |
| Weighted average by Cap. | +0.31% | -0.83% | -3.89% | -1.25% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 7T 6.12T 5.65T 5.22T 9.9T 7L 10.06T 67.48T 26.5T 3L 26.28T 25.71T 11.31L | 8L 7L 6L 6L 10.84L 7.32Cr 11.03L 73.94L 29.04L 3.6Cr 28.8L 28.17L 12Cr |
| Net income | -24.17L -21.14L -19.5L -18.01L -34.17L -23Cr -34.75L -2.33Cr -91.5L -11Cr -90.75L -88.78L -39Cr | -31.96L -27.96L -25.79L -23.82L -45.19L -30Cr -45.95L -3.08Cr -1.21Cr -15Cr -1.2Cr -1.17Cr -52Cr |
| Net Debt | 17.71L 15.49L 14.29L 13.2L 25.04L 17Cr 25.46L 1.71Cr 67.04L 8.32Cr 66.5L 65.05L 29Cr | 28.76L 25.16L 23.2L 21.43L 40.66L 27Cr 41.35L 2.77Cr 1.09Cr 14Cr 1.08Cr 1.06Cr 46Cr |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















